AQST Aquestive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%
Returns
ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.56M | $13.82M | $14.45M | $13.02M | $12.81M | $10.00M | $8.72M | $11.87M |
| Cost of revenue | $3.61M | $4.02M | $3.47M | $5.84M | $4.51M | $4.56M | $3.65M | $4.52M |
| Gross profit | $3.95M | $9.80M | $10.98M | $7.18M | $8.30M | $5.44M | $5.07M | $7.35M |
| R&D expense | $4.25M | $3.96M | $4.20M | $3.20M | $4.53M | $4.11M | $5.36M | $4.92M |
| SG&A expense | $14.17M | $14.06M | $10.98M | $32.82M | $15.25M | $12.71M | $19.07M | $16.01M |
| Operating income | -$14.47M | -$8.22M | -$4.20M | -$28.84M | -$11.48M | -$11.37M | -$19.36M | -$13.58M |
| Interest expense | $1.84M | $2.81M | $2.90M | $2.78M | $2.78M | $2.78M | $2.78M | $2.78M |
| Pretax income | -$16.50M | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -$22.93M | -$17.07M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$14,000 |
| Net income | -$16.50M | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -$22.93M | -$17.05M |
| EBITDA | -$14.31M | -$8.09M | -$4.09M | -$28.71M | -$11.34M | -$11.23M | -$19.23M | -$13.43M |
| EPS (basic) | -0.13 | -0.18 | -0.07 | — | -0.14 | -0.14 | -0.24 | — |
| EPS (diluted) | -0.13 | -0.18 | -0.07 | — | -0.14 | -0.14 | -0.24 | — |
| Weighted avg. shares (diluted) | 125.55M | 124.99M | 122.61M | — | 110.58M | 99.33M | 95.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $90.35M | $98.49M | $110.73M | $121.17M | $129.06M | $60.54M | $68.66M | $71.55M |
| Receivables | $5.25M | $9.33M | $6.87M | $17.76M | — | — | — | $7.34M |
| Inventory | $7.31M | $7.37M | $8.07M | $6.17M | $7.88M | $8.12M | $7.20M | $6.04M |
| Current assets | $105.83M | $118.49M | $130.18M | $149.27M | $151.67M | $81.72M | $89.17M | $88.22M |
| PP&E, net | $4.36M | $3.96M | $3.84M | $3.89M | $3.92M | $3.86M | $3.80M | $3.80M |
| Intangibles | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Total assets | $119.33M | $132.10M | $141.12M | $160.43M | $163.56M | $93.70M | $102.23M | $101.42M |
| Current liabilities | $17.30M | $16.48M | $31.75M | $47.61M | $25.57M | $23.16M | $18.30M | $18.86M |
| Short-term debt | $33,000 | $32,000 | — | $9.99M | — | — | — | — |
| Long-term debt | $50.76M | $50.65M | $25.10M | $27.52M | $45.00M | $45.00M | $45.00M | $32.50M |
| Total debt | $50.79M | $50.69M | $25.10M | $37.51M | $45.00M | $45.00M | $45.00M | $32.50M |
| Total liabilities | $190.15M | $188.69M | $175.18M | $194.09M | $167.67M | $166.29M | $163.16M | $161.58M |
| Shareholders' equity | -$70.82M | -$56.59M | -$34.05M | -$33.66M | -$4.11M | -$72.59M | -$60.93M | -$60.16M |
| Net debt | -$39.56M | -$47.80M | -$85.64M | -$83.66M | -$84.06M | -$15.54M | -$23.66M | -$39.05M |
| Shares outstanding | 125.69M | 125.51M | 124.28M | 122.04M | 121.66M | 99.35M | 99.32M | 91.41M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.05M | -$9.44M | -$14.81M | -$8.47M | -$12.65M | -$7.91M | -$23.40M | -$6.49M |
| Capital expenditure | $584,000 | $212,000 | $52,000 | $85,000 | $235,000 | $107,000 | $135,000 | $15,000 |
| Free cash flow | -$7.63M | -$9.65M | -$14.86M | -$8.55M | -$12.88M | -$8.02M | -$23.54M | -$6.50M |
| Investing cash flow | -$584,000 | -$212,000 | -$52,000 | -$85,000 | -$235,000 | -$107,000 | -$135,000 | -$15,000 |
| Financing cash flow | -$511,000 | -$2.59M | $4.42M | $660,000 | $81.41M | -$100,000 | $20.65M | $157,000 |
| Depreciation & amortization | $156,000 | $136,000 | $113,000 | $130,000 | $139,000 | $140,000 | $139,000 | $147,000 |
| Stock-based compensation | $2.13M | $2.90M | $2.32M | $1.38M | $2.78M | $1.88M | $1.59M | $2.40M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.